Status:
COMPLETED
Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.
Lead Sponsor:
Mary Sullivan-Whalen
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
14+ years
Phase:
PHASE1
Brief Summary
This study offers narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis vulgaris.
Detailed Description
Two groups of patients, having 10% of their body surface area involved with psoriasis vulgaris, will receive narrowband phototherapy. One group will have skin type I-IV, or light skin and the second g...
Eligibility Criteria
Inclusion
- Patients must have stable psoriasis vulgaris, which covers at least 10% of their bodies, for at least six months. Patients can not have not been treated with narrowband UVB in the past, although other light therapies are acceptable (i.e. broadband UVB and PUVA). Patients are not allowed to receive other therapies for their psoriasis, internal and topical, while they are participating in the study. Patients may continue using non-medicated moisturizer.
- \-
Exclusion
- \-
Key Trial Info
Start Date :
June 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00220025
Start Date
June 1 1999
End Date
May 1 2009
Last Update
October 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockefeller University Hospital
New York, New York, United States, 10021